The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma

Launched by ISTITUTO DI RICERCA NEUROFTALMOLOGIA S.R.L. · Jul 15, 2019

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with POAG and pseudoexfoliation glaucoma in one or both eyes. In the latter case, only one eye (chosen at random) will be used for the analysis.
• • Patients with -2 \< MD \< -15 dB, progression of MD at least -0,5 dB/y for 2 years.
• • Patients with tonometric compensation, i.e., IOP not above 18 mmHg. Tonometric compensation can be achieved with any type of hypotonic medical therapy and must be maintained during the 3 years of the study. If at any check-up the average of at least 3 measurements of IOP at different times is higher than 18 mmHg, the patient will be offered a new hypotonic treatment (including surgery) to control the progression of the disease. If compensation cannot be achieved (e.g., the patient refuses the proposed therapy or, in spite of this does not achieve satisfactory IOP values), the patient will be excluded from the study.
• • Patients over the age of 18 years
• Exclusion Criteria:
• • Patients with contraindications to citicoline
• • Patients with IOP higher than 18 mmHg
• • Patients with other forms of glaucoma
• • Patients treated with other neuroprotective therapies
• • Women who are pregnant and/or breastfeeding
• • Pediatric or adolescent patients aged under 18 years